Peptonic Medical AB (publ) (“Peptonic” or the “Company”) is adjusting its organization following the structural changes implemented in 2024. As part of this process, the need for financial functions has decreased, and the Company announces that Chief Financial Officer (CFO) Jenni Björnulfson will be leaving her position.
Over the past year, Peptonic has carried out strategic changes that have reduced the need for financial resources while shifting focus toward strengthening its commercial operations. In line with these adjustments, the Company has restructured its finance department, leading to the departure of CFO Jenni Björnulfson.
During her tenure at Peptonic, Jenni has played a key role in strengthening the Company’s financial structure and driving key strategic initiatives. She will remain in her role during the notice period.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
